These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33946560)

  • 1. Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation.
    Garcia-Perez L; van Roon L; Schilham MW; Lankester AC; Pike-Overzet K; Staal FJT
    Cells; 2021 Apr; 10(5):. PubMed ID: 33946560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Busulfan as a myelosuppressive agent for generating stable high-level bone marrow chimerism in mice.
    Peake K; Manning J; Lewis CA; Barr C; Rossi F; Krieger C
    J Vis Exp; 2015 Apr; (98):e52553. PubMed ID: 25867947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Allogeneic hematopoietic stem cell transplantations].
    Michallet M
    Transfus Clin Biol; 2011 Apr; 18(2):235-45. PubMed ID: 21466967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.
    Huston MW; Riegman AR; Yadak R; van Helsdingen Y; de Boer H; van Til NP; Wagemaker G
    Hum Gene Ther; 2014 Oct; 25(10):905-14. PubMed ID: 25222508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs.
    Down JD; Ploemacher RE
    Exp Hematol; 1993 Jul; 21(7):913-21. PubMed ID: 8100536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOD Scid Gamma Mice Are Permissive to Allogeneic HSC Transplantation without Prior Conditioning.
    Verbiest T; Finnon R; Brown N; Finnon P; Bouffler S; Badie C
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827995
    [No Abstract]   [Full Text] [Related]  

  • 7. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan administration flexibility increases the applicability of scid repopulating cell assay in NSG mouse model.
    Chevaleyre J; Duchez P; Rodriguez L; Vlaski M; Villacreces A; Conrad-Lapostolle V; Praloran V; Ivanovic Z; Brunet de la Grange P
    PLoS One; 2013; 8(9):e74361. PubMed ID: 24069300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.
    Westerhof GR; Ploemacher RE; Boudewijn A; Blokland I; Dillingh JH; McGown AT; Hadfield JA; Dawson MJ; Down JD
    Cancer Res; 2000 Oct; 60(19):5470-8. PubMed ID: 11034090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.
    Konopleva M; Benton CB; Thall PF; Zeng Z; Shpall E; Ciurea S; Kebriaei P; Alousi A; Popat U; Anderlini P; Nieto Y; Parmar S; Qiao W; Chen J; Rondon G; McMullin B; Wang RY; Lu H; Schober W; Woodworth G; Gulbis A; Cool R; Andreeff M; Champlin R
    Bone Marrow Transplant; 2015 Jul; 50(7):939-946. PubMed ID: 25867648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual effects of busulfan and irradiation on murine hematopoietic stem and progenitor cells.
    Batey K; Kim J; Brinster L; Gonzalez-Matias G; Wu Z; Solorzano S; Chen J; Feng X; Young NS
    Exp Hematol; 2022 Jan; 105():22-31. PubMed ID: 34763024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.
    Uchida N; Bonifacino A; Krouse AE; Metzger ME; Csako G; Lee-Stroka A; Fasano RM; Leitman SF; Mattapallil JJ; Hsieh MM; Tisdale JF; Donahue RE
    Exp Hematol; 2011 Jul; 39(7):795-805. PubMed ID: 21549175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
    Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice.
    Yeager AM; Shinn C; Pardoll DM
    Blood; 1991 Dec; 78(12):3312-6. PubMed ID: 1683798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier.
    Langford-Smith KJ; Sandiford Z; Langford-Smith A; Wilkinson FL; Jones SA; Wraith JE; Wynn RF; Bigger BW
    PLoS One; 2013; 8(10):e77632. PubMed ID: 24147041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.